In this regard, PDE-5 inhibitors demonstrated cardioprotective effects against cardiac remodeling, cardiac injury and LV failure [19–28] as well as PAH and RV failure both in animals [29] and humans [30]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.